Actively Recruiting
The Effect of Cardioprotective Medications on Chemotherapy-Induced Cardiotoxicity in Childhood Acute Leukemia
Led by Ain Shams University · Updated on 2025-03-03
30
Participants Needed
2
Research Sites
15 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to evaluate how cardioprotective medications affect chemotherapy-induced heart damage in children with acute leukemia. The study compares two types of heart-protecting drugs, Angiotensin-converting enzyme (ACE) inhibitors and beta-blockers, to understand their impact on heart function during cancer treatment. The study focuses on children aged 2 to 18 years and measures heart health using echocardiography. Participants receive either ACE inhibitors or beta-blockers orally, dosed by caregivers or nurses. ACE inhibitors are given at 0.3 mg per kilogram every 8 hours, while beta-blockers are administered at 0.05 mg per kilogram every 12 hours. The treatment is monitored from the start until the end of the chemotherapy induction phase, which lasts 42 days. During the study, children's heart function is assessed using 2D echocardiography to measure left ventricular ejection fraction (LVEF) at the beginning and end of the induction phase. Researchers track changes in heart performance to determine how well each medication protects the heart from chemotherapy effects. The total participation period covers these 42 days, with close monitoring of heart health and medication adherence.
CONDITIONS
Brief Title
Cardioprotection on Chemotherapy-Induced Cardiotoxicity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willingness of the legal representative of research participant to participate in the study by giving informed consent
- Ability to take oral medication
- Age 2-18 years at the time of diagnosis
You will not qualify if you...
- Documented allergy to cardioprotective medications
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 42 days
Participants receive either ACE inhibitors or β-blockers to evaluate their protective effect on chemotherapy-induced cardiotoxicity.
1 baseline visit and 1 follow-up visit
Trial Site Locations
Total: 2 locations
1
Faculty of Pharmacy, Ain Shams University
Cairo, Egypt, 11566
Actively Recruiting
2
Faculty of Pharmacy, Ain Shams University
Cairo, Egypt
Actively Recruiting
Research Team
C
Christen Said
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here